智飛生物(300122.SZ):卡介菌純蛋白衍生物(BCG-PPD)進入II期臨牀試驗
格隆匯8月15日丨智飛生物(300122.SZ)公佈,公司近日獲悉由全資子公司安徽智飛龍科馬生物製藥有限公司自主研發的卡介菌純蛋白衍生物(BCG-PPD)在深圳市第三人民醫院開展II期臨牀試驗。
卡介菌純蛋白衍生物(BCG-PPD)是公司開發的全新工藝產品。該產品的結核菌素皮膚試驗(TST)可用於結核病的輔助診斷、結核病流行病學調查及卡介苗(BCG)接種後機體免疫反應的監測。
截至公吿披露日,經查詢國家藥品監督管理局網站,國內共有兩款卡介菌純蛋白衍生物產品獲批上市。
卡介菌純蛋白衍生物(BCG-PPD)的II期臨牀試驗在深圳市第三人民醫院啟動,進行同類已上市產品對照的II期臨牀劑量標化研究。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.